Methods of identification, assessment, prevention and therapy of lung diseases and kits thereof
The invention provides biomarkers and combinations of biomarkers that are useful in diagnosing lung diseases such as non-small cell lung cancer or reactive airway disease. The invention also provides methods of differentiating lung disease, methods of monitoring therapy, and methods of predicting a subject's response to therapeutic intervention based on the extent of expression of the biomarkers and combinations of biomarkers. Kits comprising agents for detecting the biomarkers and combination of biomarkers are also provided.
1. A method of physiological characterization in a subject comprising determining the extent of expression of at least three biomarkers from Table 1 in a physiological sample of said subject, wherein the extent of expression of said at least three biomarkers are indicative of a lung disease.
2. The method of claim 1 , wherein said lung disease is reactive airway disease.
3. The method of claim 2 , wherein said reactive airway disease is asthma.
4. The method of claim 1 , wherein said method comprises determining the extent of expression of at least four biomarkers from Table 1 in a physiological sample of said subject.
5. The method of claim 4 , wherein said biomarker is a polypeptide.
6. The method of claim 1 , wherein the physiological sample is biological fluid.
7. The method of claim 6 , wherein the biological fluid is blood serum or plasma.
8. The method of claim 1 , wherein the subject is a mammal.
9. The method of claim 8 , wherein the mammal is a human.
10. The method of claim 1 , wherein the method of determining the extent of expression comprises performing a quantitative multiplex immunoassay.
11. The method of claim 1 , wherein said method comprises determining the extent of expression of at least five biomarkers from Table 1 in a physiological sample of said subject.
12. The method of claim 1 , wherein said method comprises determining the extent of expression of at least six biomarkers from Table 1 in a physiological sample of said subject.
13. The method of claim 1 , wherein said lung disease is non-small cell lung cancer.
14. The method of claim 4 , wherein said lung disease is non-small cell lung cancer.
15. The method of claim 11 , wherein said lung disease is non-small cell lung cancer.
16. The method of claim 12 , wherein said lung disease is non-small cell lung cancer.
17. The method of claim 4 , wherein said lung disease is reactive airway disease.
18. The method of claim 17 , wherein said reactive airway disease is asthma.
19. The method of claim 11 , wherein said lung disease is reactive airway disease.
20. The method of claim 19 , wherein said reactive airway disease is asthma.
21. The method of claim 12 , wherein said lung disease is reactive airway disease.
22. The method of claim 21 , wherein said reactive airway disease is asthma.
23. The method of claim 1 , wherein the subject exhibits one or more symptoms of non-small cell lung cancer or reactive airway disease.
24. The method of claim 4 , wherein the subject exhibits one or more symptoms of non-small cell lung cancer or reactive airway disease.
25. The method of claim 1 , wherein the biomarkers comprise MIF; Leptin; IL-8; IL-12 (p40), free; or combinations thereof.
26. The method of claim 4 , wherein the biomarkers comprise MIF; Leptin; IL-8; and IL-12 (p40), free.
27. The method of claim 23 , wherein the biomarkers comprise MIF; Leptin; IL-8; IL-12 (p40), free; or combinations thereof.
28. The method of claim 24 , wherein the biomarkers comprise MIF; Leptin; IL-8; and IL-12 (p40), free.